MedTrace Logo

Interleukin 6-guided Antibiotic Prescriptions in AECOPD Inpatients

NCT06612476 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 440

Last updated 2024-09-25

No results posted yet for this study

Summary

In this multicenter, prospective, randomized controlled study, we aimed to figure out, compared with the global chronic obstructive pulmonary disease initiative (GOLD) guideline -guided antibiotic therapy, whether Interleukin 6 (IL6)-guided antibiotic therapy for acute exacerbation of chronic obstructive pulmonary disease (AECOPD) can lead to a reduction in the use of antibiotics without increasing the rate of treatment failure.

Conditions

  • Chronic Obstructive Pulmonary Disease, COPD

Interventions

DRUG

Interleukin 6-guided antibiotic therapy

In Interleukin-6 group, antibiotic prescription decisions will made according to the results of IL-6.

DRUG

GOLD-guided antibiotic therapy

In guideline group, antibiotic prescription decisions will made according to the recommendations of GOLD guideline.

Sponsors & Collaborators

  • Ningbo No. 1 Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-20
Primary Completion
2026-08-31
Completion
2026-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06612476 on ClinicalTrials.gov